Recent News

Findings could improve treatment for challenging acute leukemia in children

Findings could improve treatment for challenging acute leukemia in children

There is no consensus on the best way to treat mixed phenotype acute leukemia, a rare blood cancer with survival rates of between 47 and 75 percent for children. UNC Lineberger’s Thomas Alexander, MD, and colleagues from St. Jude Children’s Research Hospital have made important discoveries about the genetics of this disease that could lead to better treatment.

Findings could improve treatment for challenging acute leukemia in children - Read More…

Smith awarded $8.5M contract to compare treatments for recurrent bladder cancer

Smith awarded $8.5M contract to compare treatments for recurrent bladder cancer

UNC Lineberger’s Angela B. Smith, MD, MS, an associate professor in the UNC School of Medicine Department of Urology and director of urologic oncology, and her collaborators were awarded a contract from the Patient-Centered Outcomes Research Institute to compare bladder removal with medical therapy in bladder cancer patients.

Smith awarded $8.5M contract to compare treatments for recurrent bladder cancer - Read More…

Johnson honored with Hyman L. Battle Distinguished Cancer Research Award

Johnson honored with Hyman L. Battle Distinguished Cancer Research Award

UNC Lineberger leaders held a reception Friday to honor Gary Johnson, PhD, the Kenan Distinguished Professor in the UNC School of Medicine Department of Pharmacology, and co-director of UNC Lineberger’s Molecular Therapeutics Program. During his 13-year tenure as chair, the Department if Pharmacology rose in national prominence and rankings. Johnson has been awarded the 2017-2018 Hyman L. Battle Distinguished Cancer Research Award.

Johnson honored with Hyman L. Battle Distinguished Cancer Research Award - Read More…

Researchers lay the foundation for personalized immune treatments for leukemia

Researchers lay the foundation for personalized immune treatments for leukemia

In the journal Blood Advances, UNC Lineberger’s Ben Vincent, MD, Paul Armistead, MD, PhD, and their collaborators reported early findings from a new study that could aid in the development of immune-based treatments that are tailored to individual leukemia patients who are undergoing stem cell transplantation.

Researchers lay the foundation for personalized immune treatments for leukemia - Read More…